MARATTO

article · Journal of Medicine in Scientific Research

One-Year Single Center Initial Experience of Supine PCNL

2024Open accessDamanhour University

Abstract

Objectives: to study the safety and efficacy of supine position in percutaneous nephrolithotomy in treatment of large renal stones. Methods: A retrospective study included 51 patients with large renal stones (more than 2 cm) planned for PCNL operation underwent percutaneous nephrolithotomy (PCNL) in modified flank supine position from October 2022 till August 2023. We excluded from this study as uncorrectable coagulopathy, active urinary tract infection (UTI), and pediatric patients, younger than 18 years. The study protocol was approved by Damanhur National Medical Institute (HD000188/22/11/2023). Results: The most common site of stone was renal pelvis in 17 cases (33.3%) then stag horn 11 (21.6%) followed by pelvis and middle calyx 10 (19.6%). Residual stone, drop of hemoglobin, need of blood transfusion were found in 13.7%, 13.7%, 2.0% respectively. shockwave lithotripsy (SWL) and second look PCNL as auxiliary procedures were done in 15.7%, and 5.9% of patients respectively. The most postoperative complication was fever found in 3 (5.9%) of patients then hemorrhage 2 (3.9%) followed by urine leakage 1 (2.0%). Hounsfield unit, operative time and hospital stays were the most common factors predisposing to post operative complications (P

Research topics

  • Education and Military Integration
  • Colorectal and Anal Carcinomas

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.59299/2537-0928.1073

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.